CJC-1295 (no-DAC) + Ipamorelin Blend Research Evidence
The CJC-1295 (no-DAC) + Ipamorelin Blend evidence base: trials, journals, and what the data does not yet show.
Key Takeaways
CJC-1295 is a lab-made peptide that tells the pituitary gland to release more growth hormone and IGF-1 . It comes in two forms: with DAC , which lasts longer, and without DAC , which wears off much faster. CJC-1295 is not FDA-approved , is banned by WADA, and may carry heart and blood sugar risks. CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone (GH) and insulin-like growth factor 1 (IGF-1). Clinical research demonstrated that single injections increase GH levels 2- to 10-fold for six or more days and elevate IGF-1 levels 1.5- to 3-fold for 9–11 days. Enhanced fat metabolism and body composition Improved recovery from exercise and injury Potential anti-aging effects through elevated IGF-1 levels Increased collagen synthesis and skin elasticity
Pulsatile vs. Sustained GH Release
CJC-1295 without DAC produces a more pulsatile pattern of GH release, which some researchers believe better mimics natural physiology. The body normally releases GH in pulses, with the largest occurrence during deep sleep. CJC-1295 with DAC creates more sustained elevation of GH and IGF-1 levels, which may benefit certain therapeutic applications but potentially blunts the natural pulsatile rhythm.
IGF-1 Axis Activation
Beyond direct GH stimulation, CJC-1295 activates the broader GH/IGF-1 axis. Elevated GH stimulates the liver to produce IGF-1, which mediates many of growth hormone's anabolic effects on muscle, bone, and other tissues. Clinical trials showed IGF-1 levels remained elevated above baseline for up to 28 days following multiple doses.
Results Timelines
Weeks 1–2: Most users report improved sleep quality and more vivid dreams. Some experience mild water retention and increased appetite. Weeks 2–4: Enhanced recovery from workouts becomes noticeable. Some users report improved skin quality and minor fat loss. Weeks 4–8: More significant changes in body composition typically emerge, including increased muscle fullness and continued fat reduction. Strength gains may become apparent. Weeks 8–12: Cumulative effects peak, with users often reporting the most dramatic improvements in lean mass, recovery, and overall body composition. Clinical research supports this timeline, showing IGF-1 levels remained elevated above baseline for up to 28 days with repeated dosing, suggesting cumulative benefits.
Research Evidence
The most significant clinical study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism in 2006. This randomized, placebo-controlled, double-blind trial examined pharmacokinetics, pharmacodynamics, and safety in healthy adults aged 21–61. Single injections produced dose-dependent increases in GH concentrations of 2- to 10-fold lasting 6 or more days IGF-1 levels increased 1.5- to 3-fold for 9–11 days after a single dose Multiple doses produced cumulative effects, with IGF-1 remaining elevated above baseline for up to 28 days No serious adverse reactions were reported The peptide was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg Animal Research: A study published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 normalized growth in GH-deficient models, supporting its potential therapeutic applications. Additional Study (2009): Research published in Growth Hormone & IGF Research further confirmed the activation of the GH/IGF-1 axis by CJC-1295, establishing its efficacy as a long-acting GHRH analog. Important Note: A Phase II clinical trial investigating CJC-1295 for HIV-associated lipodystrophy was halted in 2006 following a patient death, though the relationship to the study drug was not definitively established.
Legal Status / FDA
CJC-1295 is not FDA-approved for human use. It exists in a regulatory gray area . It can be legally purchased for research purposes only but is not approved for human consumption or medical treatment. In December 2024, the FDA's Pharmacy Compounding Advisory Committee discussed CJC-1295 among other peptides, with the agency expressing concerns about cardiac risks and the potential for peptide impurities in compounded preparations. The FDA has moved to restrict compounding pharmacies from producing certain peptides, including CJC-1295, citing safety concerns and lack of adequate clinical data. Internationally, regulations vary significantly. Some countries permit peptide sales with fewer restrictions, while others classify them as controlled substances. Not FDA-approved for any medical indication Cannot legally be sold as a drug, food, or dietary supplement for human consumption Legally sold as a "research chemical" not intended for human use Compounding pharmacy restrictions were significantly tightened in late 2024
References
- Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. · Hoffmann P, Feige JJ, Alfaidy N · 2006
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. · Sackmann-Sala L, Ding J, Frohman LA et al. · 2009
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. · Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH · 1998
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. · Beck DE, Sweeney WB, McCarter MD et al. · 2014
- Ipamorelin | C38H49N9O5 | CID 9831659 - PubChem - NIH
- Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005. · Chung S, Son GH, Park SH, Park E, Lee KH, Geum D, Kim K · 2005
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. · Teichman SL, Neale A, Lawrence B et al. · 2006
- Hansen BS, et al. The growth hormone secretagogue ipamorelin: pharmacological profile. Endocrinology. 1999;140(11):5552-5561. · Cowen ME, Miles BJ, Cahill DF, Giesler RB, Beck JR, Kattan MW · 1998
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. · Gobburu JV, Agersø H, Jusko WJ et al. · 1999
- Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006. · Zaidi D, James KA, Wagner GF · 2006
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. · Ionescu M, Frohman LA · 2006